Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 41% below Graham Number ($8.22) — significant margin of safety
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 38.5% with 1,054.5% net margin
- Revenue growing at 66% annually
ABEONA THERAPEUTICS INC. (ABEO) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $275 million . Key value metrics: P/E ratio 4.5, P/B ratio 1.73, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ABEONA THERAPEUTICS INC. — Fundamental Analysis Summary
ABEONA THERAPEUTICS INC. (ABEO) is trading 41% below its Graham Number of $8.22 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 4.5x.
On financial health, ABEO shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 38.5% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.13.
StockPik's composite Value Score for ABEO is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ABEO reports a high gross margin of 73.7% (sector average: 33.5%) and a negative operating margin of -1,406.9%.
ABEO shows revenue growing at 66% year-over-year, with earnings growing at 212%.